ROCK 1 is a potential combinatorial drug target for BRAF mutant melanoma

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: Online-Ressource

Language: Englisch

Bibliographic citation: ROCK 1 is a potential combinatorial drug target for BRAF mutant melanoma ; volume:10 ; number:12 ; year:2014 ; extent:15
Molecular systems biology ; 10, Heft 12 (2014) (gesamt 15)

Creator: Smit, Marjon A.
Maddalo, Gianluca
Greig, Kylie
Raaijmakers, Linsey M.
Possik, Patricia A.
van Breukelen, Bas
Cappadona, Salvatore
Heck, Albert JR
Altelaar, AF Maarten
Peeper, Daniel S.

DOI: 10.15252/msb.20145450

URN: urn:nbn:de:101:1-2023011406072014833491

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:31 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Smit, Marjon A.
Maddalo, Gianluca
Greig, Kylie
Raaijmakers, Linsey M.
Possik, Patricia A.
van Breukelen, Bas
Cappadona, Salvatore
Heck, Albert JR
Altelaar, AF Maarten
Peeper, Daniel S.

Other Objects (12)

Optimizing the treatment of BRAF mutant melanoma

Novel combination therapies for BRAF-mutant melanoma

WNT5A-ROR2 axis mediates VEGF dependence of BRAF mutant melanoma

Inhibition of mitochondrial respiration prevents BRAF-mutant melanoma brain metastasis

Sequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned

Stopping targeted therapy for complete responders in advanced BRAF mutant melanoma

Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma

Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

Paraneoplastic Cerebellar Degeneration Secondary to BRAF Mutant Melanoma Metastasis from an Occult Primary Cancer

Circulating tumor DNA allows early treatment monitoring in BRAF- and NRAS-mutant malignant melanoma

SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma

Optimizing the treatment of BRAF mutant melanoma

Novel combination therapies for BRAF-mutant melanoma

WNT5A-ROR2 axis mediates VEGF dependence of BRAF mutant melanoma

Inhibition of mitochondrial respiration prevents BRAF-mutant melanoma brain metastasis

Sequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned

Stopping targeted therapy for complete responders in advanced BRAF mutant melanoma

Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma

Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

Paraneoplastic Cerebellar Degeneration Secondary to BRAF Mutant Melanoma Metastasis from an Occult Primary Cancer

Circulating tumor DNA allows early treatment monitoring in BRAF- and NRAS-mutant malignant melanoma

SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma

Optimizing the treatment of BRAF mutant melanoma

Novel combination therapies for BRAF-mutant melanoma

WNT5A-ROR2 axis mediates VEGF dependence of BRAF mutant melanoma

Inhibition of mitochondrial respiration prevents BRAF-mutant melanoma brain metastasis

Sequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned

Stopping targeted therapy for complete responders in advanced BRAF mutant melanoma

Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma

Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

Paraneoplastic Cerebellar Degeneration Secondary to BRAF Mutant Melanoma Metastasis from an Occult Primary Cancer

Circulating tumor DNA allows early treatment monitoring in BRAF- and NRAS-mutant malignant melanoma

SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

ROCK 1 is a potential combinatorial drug target for BRAF mutant melanoma

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Optimizing the treatment of BRAF mutant melanoma

Novel combination therapies for BRAF-mutant melanoma

WNT5A-ROR2 axis mediates VEGF dependence of BRAF mutant melanoma

Inhibition of mitochondrial respiration prevents BRAF-mutant melanoma brain metastasis

Sequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned

Stopping targeted therapy for complete responders in advanced BRAF mutant melanoma

Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma

Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

Paraneoplastic Cerebellar Degeneration Secondary to BRAF Mutant Melanoma Metastasis from an Occult Primary Cancer

Circulating tumor DNA allows early treatment monitoring in BRAF- and NRAS-mutant malignant melanoma

SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma

Optimizing the treatment of BRAF mutant melanoma

Novel combination therapies for BRAF-mutant melanoma

WNT5A-ROR2 axis mediates VEGF dependence of BRAF mutant melanoma

Inhibition of mitochondrial respiration prevents BRAF-mutant melanoma brain metastasis

Sequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned

Stopping targeted therapy for complete responders in advanced BRAF mutant melanoma

Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma

Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

Paraneoplastic Cerebellar Degeneration Secondary to BRAF Mutant Melanoma Metastasis from an Occult Primary Cancer

Circulating tumor DNA allows early treatment monitoring in BRAF- and NRAS-mutant malignant melanoma

SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma

Optimizing the treatment of BRAF mutant melanoma

Novel combination therapies for BRAF-mutant melanoma

WNT5A-ROR2 axis mediates VEGF dependence of BRAF mutant melanoma

Inhibition of mitochondrial respiration prevents BRAF-mutant melanoma brain metastasis

Sequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned

Stopping targeted therapy for complete responders in advanced BRAF mutant melanoma

Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma

Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

Paraneoplastic Cerebellar Degeneration Secondary to BRAF Mutant Melanoma Metastasis from an Occult Primary Cancer

Circulating tumor DNA allows early treatment monitoring in BRAF- and NRAS-mutant malignant melanoma

SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma

Related objects

Reset password